Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2021 | Lymphoma | Letter to the Editor

Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma

Authors: Wei Qin, Xufeng Jiang, Jianhua You, Rui Guo, Qing Shi, Lei Dong, Rong Shen, Shu Cheng, Pengpeng Xu, Ying Qian, Biao Li, Li Wang, Weili Zhao

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2021

Excerpt

Dear Sir, …

Lazarovici J, Terroir M, Arfi-Rouche J, Michot JM, Mussot S, Florea V, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017;44:2018–24.CrossRef

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRef

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.CrossRef

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60.CrossRef

Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130:267–70.CrossRef

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–9.CrossRef

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.CrossRef

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9.CrossRef

Title: Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma
Authors: Wei Qin
Xufeng Jiang
Jianhua You
Rui Guo
Qing Shi
Lei Dong
Rong Shen
Shu Cheng
Pengpeng Xu
Ying Qian
Biao Li
Li Wang
Weili Zhao
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Rituximab
Rituximab
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05310-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Deauville score evaluation of interim PET/CT in primary mediastinal large B-cell lymphoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2021

Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologists

Convolutional neural networks for PET functional volume fully automatic segmentation: development and validation in a multi-center setting

Diffuse cerebellar hypermetabolism: an early sign of leptomeningeal metastases

Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms

An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation

Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy